Advertisement

Volume 1, Issue 18

 

Cover Image

Cover Figure: Aberrant release of platelets into bone marrow of mice lacking Arp2/3 function in the megakaryocytic lineage. See the article by Paul et al.

WASHINGTON, August 8,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

 

Animal studies have been critical for our understanding of many diverse biological processes. However, a frequent question is how many mice are required to reach important end points with the smallest possible number of animals for both humanitarian and cost reasons. In a Blood Advances Talk, Donna Neuberg discusses this important issue.

RUNX1 mutations have been shown to contribute to myeloid diseases especially in patients with myelodysplastic syndromes. Sakurai et al evaluated the different isoforms of RUNX1 in a cohort of these patients, demonstrating a potential role for RUNX1a in the disease process.

Checkpoint inhibitors have proven to be a remarkably effective treatment for patients with Hodgkin lymphoma. The identification of patients who might benefit from this therapy as a front line approach is of considerable interest. Hollander et al found that the role of PD-1and PD-L1+ expressing lymphocytes in the tumor microenvironment is associated with an inferior outcome.

 

Tyrosine kinase inhibitors such as imatinib have revolutionized the treatment of chronic myeloid leukemia (CML). However, not all patients have outstanding responses, and predicting who those patients may be could help provide more effective and definitive therapy. Marum et al studied ASLX1 and BIM germ line variants to predict response and to identify patients with CML who are likely to have a less-than-optimal response.

The role of key genes in the function of platelets is of critical importance to understand the biology and develop therapeutics for this critical component of hemostasis and wound healing. Paul et al, evaluate the role of the Arp2/3 complex in megakaryocytes with interesting and important consequences.

 


Featured Visual Abstract

Dynamic change of transcription pausing through modulating NELF protein stability regulates granulocytic differentiation

The mechanisms underlying the differentiation of hematopoietic stem and progenitor cells to mature effector cells are an area of intense investigation. Liu et al explore the role of the NELF complex and transcriptional pausing in granulocytic differentiation, with interesting and important findings.

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.